← Back to Profile Company Fact Sheet

Innovacell Co., Ltd.

504A イノバセル株式会社
Biotechnology · TSE
PRICE: ¥511 · MKT CAP: ¥17.0B · P/E: · P/B: · DIV YIELD: 0.0%
PRICE — 5Y
Characteristics & Business Summary
Innovacell Inc. develops, manufactures, and sells cell therapy and regenerative medicine products. The company's products include ICEF15, a cell treatment for urgent fecal incontinence; ICEF16, a cell therapy for leaky fecal incontinence; and ICES13, a cell...
Income Statement Highlights (¥ Million, except EPS/DPS in ¥)
Fiscal Period FY 2025
Net Sales
Operating Profit -2,232
Ordinary Profit -2,854
Net Profit -2,855
EPS ¥-86
DPS ¥0
Balance Sheet & Valuation Highlights
Total Assets ¥5B
Net Assets (Equity) ¥-1B
Equity Ratio -12.4%
ROE (Return on Equity)
Cash & Equivalents ¥4B
Interest-Bearing Debt ¥5B
Capital Expenditure (CapEx) ¥0B
Depreciation & Amort. ¥0B
Major Shareholders
  • 1. Peppermint Grove Limited 10.8%
  • 2. INSANNA Stiftung 10.8%
  • 3. シーズ・インベストメント有限責任事業組合 7.4%
  • 4. ノビック・コーリン 6.9%
  • 5. シーガー・ジェイソン 6.9%
  • 6. マークシュタイナー・ライナー 6.4%
  • 7. 坂野 敦 4.9%
  • 8. Glymur Biotech Ventures LP 4.0%
  • 9. アルフレッサ株式会社 3.5%
  • 10. 山田 敏治 2.4%
Activist Activity
Colin Lee Novick 5.41%
2026-06-08 · decrease
M&G Investment Management Limited 8.99%
2026-03-06 · initial_5pct
SHIRONO YOSHINORI 6.11%
2026-03-03 · initial_5pct
Colin Lee Novick 5.49%
2026-03-02 · initial_5pct
Jason Sieger 5.49%
2026-03-02 · initial_5pct
Historical Per-Share Data & Valuation Ratios
Per Share Metric FY 2025
Revenues per share
FCF/Share ¥-61
EPS ¥-86
DPS ¥0
Capital Spending per share ¥1
Book Value per share ¥-57
Common Shares Outstanding 33M
Financial Aggregates & Margins
Financial Aggregate FY 2025
Revenues (Net Sales)
Operating Margin (%)
Net Profit (owners) ¥-3B
Net Profit Margin (%)
Working Capital ¥-1B
Total Debt (Interest-bearing) ¥5B
Net Worth (Common Equity) ¥-2B
Return on Total Assets (ROA) -56.1%
Return on Common Equity (ROE)
Business Summary & Analysis
Innovacell Inc. develops, manufactures, and sells cell therapy and regenerative medicine products. The company's products include ICEF15, a cell treatment for urgent fecal incontinence; ICEF16, a cell therapy for leaky fecal incontinence; and ICES13, a cell...
Capital Strategy Targets
No active capital policy disclosure records found.
Tokyo Intelligence Filings System · Company Fact Sheet Generative Extraction Layer (Sonnet/Haiku) · Date: 2026-06-13